An Injectable Gel for a Single-Dose mRNA Vaccine
Injectable Hydrogel Depots for Self-replicating mRNA Vaccine Delivery
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11088790
This project is creating a new kind of injectable gel that delivers a special mRNA vaccine to protect people from serious Staph infections with just one shot.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11088790 on ClinicalTrials.gov |
What this research studies
This research aims to develop a novel injectable vaccine delivery system to combat severe Staphylococcus aureus (Staph) infections. The system uses a biodegradable gel that contains a self-replicating mRNA vaccine, designed to teach your body how to fight off the infection. The goal is to provide strong, long-lasting protection with just a single injection, offering a significant improvement over current vaccine delivery methods. This innovative approach could help prevent life-threatening Staph infections that are currently responsible for many deaths each year.
Who could benefit from this research
Good fit: Ideal candidates would be individuals at high risk for severe Staphylococcus aureus infections, such as those undergoing surgery, with catheters, or with prosthetic devices.
Not a fit: Patients already suffering from an active Staphylococcus aureus infection would likely not benefit from this preventative vaccine.
Why it matters
Potential benefit: If successful, this could offer a highly effective, single-dose vaccine to prevent life-threatening Staphylococcus aureus infections, which currently cause many deaths.
How similar studies have performed: While components like cationic polymers and biodegradable gels have been reported, this specific combination for a self-replicating mRNA vaccine depot represents a novel approach to vaccine delivery.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRYERS, JAMES D. — UNIVERSITY OF WASHINGTON
- Study coordinator: BRYERS, JAMES D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus